NCT05010005
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 24 versions: 13 with changes below, 11 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 20 words Show 4 more changesShow less
- Primary endpoints: details revised at 1 of 1 entry
- Enrollment closed, study ongoing
- Final enrollment: 80 participants (planned 70)
- Site details revised at 9 of 9 sites
- Minor Site details revised at 1 of 9 sitesv20
- Notable Primary and study completion dates: Aug 2026 to Aug 2027
- Eligibility criteria expanded, about 4 words
Notable Trial status: Active, Not Recruiting to Recruitingv17 Show 5 more changesShow less
- Primary and study completion dates: Aug 2025 to Aug 2026
- Eligibility criteria expanded, about 129 words
- Enrollment target: 49 to 70
- Secondary endpoints expanded, about 18 words
- Site details revised at 9 of 9 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 52 to confirmed 49
- Site details revised at 9 of 9 sites
Show 7 earlier versionsHide 7 earlier versions
- Notable Primary and study completion dates: Aug 2024 to Aug 2025
- Eligibility criteria expanded, about 23 words
- Notable Eligibility criteria expanded, about 14 wordsv11
- Notable Eligibility criteria revisedv8
- Minor Study sites: 8 to 9v7
- Minor Study sites: 7 to 8v6
- Notable Primary and study completion dates: Aug 2023 to Aug 2024v5
- Notable Eligibility criteria expanded, about 4 wordsv4
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
Ruxolitinib 20mg BID plus Duvelisib 25mg, 50mg, or 75mg BID. Patients will be instructed to take duvelisib and ruxolitinib by mouth every 12 hours, the same time each day, +/- 2 hours. Duvelisib and ruxolitinib will be provided via the institutional investigational pharmacy. The researchers will utilize a dose-escalation standard 3+3 design in which we evaluate 3 doses of duvelisib (25mg BID, 50mg BID, and 75mg BID) in combination with ruxolitinib 20mg BID. A minus-1 dose level of duvelisib (15mg BID) can be used if de-escalation is needed. The cohort expansion phase will have two treatment groups JAK/STAT activation or mutation present or JAK/STAT activation or mutation absent or unknown. Upon discussion with PI, the treating physician may increase dose up to 20 mg of ruxotlinib and/or 25 mg of duvelisib when deemed clinically favorable. T-prolymphocytic leukemia (T-PLL) and T-follicular helper (TFH) lymphoma expansion: Further expansion for patients with T-PLL and TFH lymphomas.
Drugs: Ruxolitinib, Duvelisib
Sites
9 sites in 1 country